The advent of hybridoma technology leading to the successful produc tion of monoclonal antibodies against a variety of tumor-associated antigens has, during the last decade, provided a very powerful tool for research and clinical investigations. These highly specific reagents have essentially replaced the polysera of the earlier days. The successful demonstration of the many wide ranging capabilities of the monoclonal antibody technique has already begun to exert an enormous impact on diverse areas of research in basic science and medicine. In particular, the potential of monoclonal antibodies…mehr
The advent of hybridoma technology leading to the successful produc tion of monoclonal antibodies against a variety of tumor-associated antigens has, during the last decade, provided a very powerful tool for research and clinical investigations. These highly specific reagents have essentially replaced the polysera of the earlier days. The successful demonstration of the many wide ranging capabilities of the monoclonal antibody technique has already begun to exert an enormous impact on diverse areas of research in basic science and medicine. In particular, the potential of monoclonal antibodies to serve as carriers for selective targeting of radionuclides to tumors for diagnosis or therapy, has stimulated an intense surge of research interest and even revived hopes of realizing Ehrlich's concept of the "magic bullet". Indeed, the technology appears to be on the threshold of a revolution in diagnosing and treating malignant disease. Much work remains to be done, however, and even though the progress has been impressive, results to date have shown only moderate success. There is no question that the limited success we have achieved thus far is merely a prelude to the many more exciting developments yet to come.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Immunochemistry of Hybridomas.- Characterization and Selection Criteria of Monoclonal Antibodies for Tumor Imaging Studies.- Tumor Markers and Their Relevance in the Design of Radioimmunoimaging Experiments.- Selection of Monoclonal Antibodies with Optimal Biological Functions for Clinical Application.- Selection and Utilization of Monoclonal Antibody Defined Melanoma Associated Antigens for Immunoscintigraphy in Patients with Melanoma.- Development and Characterization of Human Monoclonal Antibodies and Their Application in the Radioimmunodetection of Colon Carcinoma.- Progress in Diagnostic Immunoscintigraphy and First Approach to Radioimmunotherapy of Colon Carcinoma.- The Design of a Radiolabeled Monoclonal Antibody for Radioimmunodiagnosis and Radioimmunotherapy.- Immunohistochemistry and Correlation with Plasma Levels of CA 19-9 and CEA in Gastrointestinal Tumors.- Optimization of Mouse IgG Fragmentation Technique in the Selection of Monoclonal Antibodies for Myocardial Infarct Imaging.- Sensitivity and Efficacy Indices for Oncologic Data Reporting.- Production and Use of Prospective Radionuclides for Radioimmunotherapy.- Criteria for the Selection of Nuclides for Radioimmunotherapy.- Experience with Iodine-123 Labeled Antibodies.- Radiohalogenation of Antibodies: Chemical Aspects.- Radiohalogenation of Monoclonal Antibodies: Experiences with Radioiodination of Monoclonal Antibodies for Radioimmunotherapy.- Use of Bifunctional Chelating Agents for Radiolabeling Antibodies.- Monoclonal Antibody Labeling with Indium-111 and Gadolinium via DTPA Chelation on Selective and Nonselective Sites of the Antibody.- Important Chemical Variables for Labeling Antibodies with Indium-111 and Technetium-99m.- Potential Labeling of Monoclonal Antibodies with Positron Emitters.- Quantitative Pharmacokinetics of Radiolabeled Monoclonal Antibodies for Imaging and Therapy in Patients.- Kinetic Analysis with Probability Mapping in Radioimmunoscintigraphy.- Biokinetic Studies and Scintigraphic Imaging of Human Carcinoma Xenografts with Radiolabeled Monoclonal Antibodies.- Use of an Animal Model System for Evaluating Labeled Monoclonal Antibodies.- Antibody-Hapten Complexes for Imaging.- Antibody - Carboxypeptidase G2 Conjugates as Potential Tumor Imaging Agents.- In Vivo Kinetics of Iodine-131-Monoclonal Antibodies [anti-CEA and 19-9, F(ab?)2] in Humans.- The National Institutes of Health Experience with Radiolabeled Monoclonal Antibodies: Lymphoma, Melanoma, and Colon Cancer.- Adjuvant Radioimmunotherapy for Micrometastases: A Strategy for Cancer Cure.- Quantitative Imaging and Internal Radiation Dosimetry in the Therapeutic Use of Labeled Monoclonal Antibodies.- The Distribution of Halogenated (At-211 or I-125) Tumor Specific Antibody in Tumor Bearing and Control Mice.- State-of-the-Art and Performance Testing of Instrumentation for the Scintigraphic Detection of Tumors with Labeled Monoclonal Antibodies.- Theoretical Limitations of Tumor Imaging.- Image Subtraction Techniques in Immunoscintigraphy.- Digital Superimposition of Single Photon Emission Computerized Tomography (SPECT) and CT Images for Immunoscintigraphy.- Radioimmunoscintigraphy - SPECT With I-131-MAbs; Comparison with TCT in the Follow-up of Colorectal Cancer.- Comparative Prospective Detection of Recurrences of Carcinomas with SPECT Imaging Using Radiolabeled Monoclonal Antibodies, Ultrasonography and Computed Tomography.- NMR Enhancement with Gd Labeled Antibodies.- Preclinical and Clinical Studies with Indium-111 anti-CEA Antibodies and Fragments.- Clinical Experience inCancer Diagnosis with Radiolabeled Monoclonal Antibodies in 200 Patients and Initial Attempts at Radioimmunotherapy.- Tumor Radioimmunodetection by anti-Melanoma and anti-CEA Monoclonal Antibodies: Pilot and Prospective Studies.- Tumor Immunoscintigraphy: Multicenter Clinical Trials of the Italian National Research Council (CNR).- Interstitial and Intravenous Application of Monoclonal Antibody F(ab?)2 Fragments in the Detection of Lymph Node Metastases: Benefits and Problems with Both Routes of Administration.- Radioimaging of Melanoma and CEA Secreting Tumors by Monoclonal Antibodies Performed by Different Routes of Administration.- A Monoclonal Antibody (Po66-2) Reactive with Human Lung Squamous Cell Carcinoma - Cell Reactivity In Vitro and Preliminary Scintigraphic Trials.- Monoclonal Antibodies Against Human Osteosarcoma: Preliminary Studies.- Radioimmunotherapy of Cancer: Historical Perspectives and Prospects for the Future.- Recent Perspectives on the Use of Radiolabeled Monoclonal Antibodies for Immunotherapy.- Intraperitoneal Therapy of Ovarian Cancer with Radiolabeled Monoclonal Antibodies.- Radioactive Monoclonal Antibodies Against Cell Surface Antigens for Labeling Leukocyte Subpopulations.- Monoclonal Antibody Against Human Fibrin for Imaging Thrombi.- Radiolabeled Antiplatelet Monoclonal Antibodies for the Scintigraphic Localization of In-vivo Thrombi and Vascular Lesions.- Potential of Radiolabeled Antiplatelet Antibodies in the Detection of Vascular Thrombi.- List of Participants.- Author Index.
Immunochemistry of Hybridomas.- Characterization and Selection Criteria of Monoclonal Antibodies for Tumor Imaging Studies.- Tumor Markers and Their Relevance in the Design of Radioimmunoimaging Experiments.- Selection of Monoclonal Antibodies with Optimal Biological Functions for Clinical Application.- Selection and Utilization of Monoclonal Antibody Defined Melanoma Associated Antigens for Immunoscintigraphy in Patients with Melanoma.- Development and Characterization of Human Monoclonal Antibodies and Their Application in the Radioimmunodetection of Colon Carcinoma.- Progress in Diagnostic Immunoscintigraphy and First Approach to Radioimmunotherapy of Colon Carcinoma.- The Design of a Radiolabeled Monoclonal Antibody for Radioimmunodiagnosis and Radioimmunotherapy.- Immunohistochemistry and Correlation with Plasma Levels of CA 19-9 and CEA in Gastrointestinal Tumors.- Optimization of Mouse IgG Fragmentation Technique in the Selection of Monoclonal Antibodies for Myocardial Infarct Imaging.- Sensitivity and Efficacy Indices for Oncologic Data Reporting.- Production and Use of Prospective Radionuclides for Radioimmunotherapy.- Criteria for the Selection of Nuclides for Radioimmunotherapy.- Experience with Iodine-123 Labeled Antibodies.- Radiohalogenation of Antibodies: Chemical Aspects.- Radiohalogenation of Monoclonal Antibodies: Experiences with Radioiodination of Monoclonal Antibodies for Radioimmunotherapy.- Use of Bifunctional Chelating Agents for Radiolabeling Antibodies.- Monoclonal Antibody Labeling with Indium-111 and Gadolinium via DTPA Chelation on Selective and Nonselective Sites of the Antibody.- Important Chemical Variables for Labeling Antibodies with Indium-111 and Technetium-99m.- Potential Labeling of Monoclonal Antibodies with Positron Emitters.- Quantitative Pharmacokinetics of Radiolabeled Monoclonal Antibodies for Imaging and Therapy in Patients.- Kinetic Analysis with Probability Mapping in Radioimmunoscintigraphy.- Biokinetic Studies and Scintigraphic Imaging of Human Carcinoma Xenografts with Radiolabeled Monoclonal Antibodies.- Use of an Animal Model System for Evaluating Labeled Monoclonal Antibodies.- Antibody-Hapten Complexes for Imaging.- Antibody - Carboxypeptidase G2 Conjugates as Potential Tumor Imaging Agents.- In Vivo Kinetics of Iodine-131-Monoclonal Antibodies [anti-CEA and 19-9, F(ab?)2] in Humans.- The National Institutes of Health Experience with Radiolabeled Monoclonal Antibodies: Lymphoma, Melanoma, and Colon Cancer.- Adjuvant Radioimmunotherapy for Micrometastases: A Strategy for Cancer Cure.- Quantitative Imaging and Internal Radiation Dosimetry in the Therapeutic Use of Labeled Monoclonal Antibodies.- The Distribution of Halogenated (At-211 or I-125) Tumor Specific Antibody in Tumor Bearing and Control Mice.- State-of-the-Art and Performance Testing of Instrumentation for the Scintigraphic Detection of Tumors with Labeled Monoclonal Antibodies.- Theoretical Limitations of Tumor Imaging.- Image Subtraction Techniques in Immunoscintigraphy.- Digital Superimposition of Single Photon Emission Computerized Tomography (SPECT) and CT Images for Immunoscintigraphy.- Radioimmunoscintigraphy - SPECT With I-131-MAbs; Comparison with TCT in the Follow-up of Colorectal Cancer.- Comparative Prospective Detection of Recurrences of Carcinomas with SPECT Imaging Using Radiolabeled Monoclonal Antibodies, Ultrasonography and Computed Tomography.- NMR Enhancement with Gd Labeled Antibodies.- Preclinical and Clinical Studies with Indium-111 anti-CEA Antibodies and Fragments.- Clinical Experience inCancer Diagnosis with Radiolabeled Monoclonal Antibodies in 200 Patients and Initial Attempts at Radioimmunotherapy.- Tumor Radioimmunodetection by anti-Melanoma and anti-CEA Monoclonal Antibodies: Pilot and Prospective Studies.- Tumor Immunoscintigraphy: Multicenter Clinical Trials of the Italian National Research Council (CNR).- Interstitial and Intravenous Application of Monoclonal Antibody F(ab?)2 Fragments in the Detection of Lymph Node Metastases: Benefits and Problems with Both Routes of Administration.- Radioimaging of Melanoma and CEA Secreting Tumors by Monoclonal Antibodies Performed by Different Routes of Administration.- A Monoclonal Antibody (Po66-2) Reactive with Human Lung Squamous Cell Carcinoma - Cell Reactivity In Vitro and Preliminary Scintigraphic Trials.- Monoclonal Antibodies Against Human Osteosarcoma: Preliminary Studies.- Radioimmunotherapy of Cancer: Historical Perspectives and Prospects for the Future.- Recent Perspectives on the Use of Radiolabeled Monoclonal Antibodies for Immunotherapy.- Intraperitoneal Therapy of Ovarian Cancer with Radiolabeled Monoclonal Antibodies.- Radioactive Monoclonal Antibodies Against Cell Surface Antigens for Labeling Leukocyte Subpopulations.- Monoclonal Antibody Against Human Fibrin for Imaging Thrombi.- Radiolabeled Antiplatelet Monoclonal Antibodies for the Scintigraphic Localization of In-vivo Thrombi and Vascular Lesions.- Potential of Radiolabeled Antiplatelet Antibodies in the Detection of Vascular Thrombi.- List of Participants.- Author Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
